Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Iscoms.

B Morein1

  • 1Department of Virology, National Veterinary Institute, Uppsala, Sweden.

Veterinary Microbiology
|June 1, 1990
PubMed
Summary
This summary is machine-generated.

Immunostimulating complexes (iscoms) effectively present antigens in multimeric form, enhancing immunogenicity. These novel particles induce robust immune responses and protective immunity against viral infections and tumors.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of the humoral immune response to a multicomponent recombinant vaccine against S. aureus in healthy pregnant heifers.

Veterinary journal (London, England : 1997)·2018
Same author

Immune response and functional role of antibodies raised in heifers against a Staphylococcus aureus CP5 lysate and recombinant antigens vaccine formulated with Iscom Matrix adjuvant.

Veterinary immunology and immunopathology·2014
Same author

The ISCOM: an immunostimulating complex.

Immunology today·2014
Same author

Immune responsiveness in the neonatal period.

Journal of comparative pathology·2007
Same author

Comparison of intranasal with targeted lymph node immunization using PR8-Flu ISCOM adjuvanted HIV antigens in macaques.

Journal of medical virology·2007
Same author

Antibody responses to human rotavirus (HRV) in gnotobiotic pigs following a new prime/boost vaccine strategy using oral attenuated HRV priming and intranasal VP2/6 rotavirus-like particle (VLP) boosting with ISCOM.

Clinical and experimental immunology·2004
Same journal

A divalent nanoparticle vaccine confers robust protective immunity against serotype O FMDV and SVA in pigs.

Veterinary microbiology·2026
Same journal

A Lactobacillus plantarum vaccine candidate with dendritic cell targeting and lysosome escape properities provides efficient protection against necrotic enteritis in broiler chickens.

Veterinary microbiology·2026
Same journal

Tracheal transcriptional response to challenge with virulent Mycoplasma gallisepticum in chickens spray vaccinated with the Vaxsafe MG304 live-attenuated vaccine.

Veterinary microbiology·2026
Same journal

Intermittent shedding dynamics of EHV-1 across biological matrices during a natural outbreak linked to international equestrian events.

Veterinary microbiology·2026
Same journal

Development of a replication-restricted, esterase-deficient influenza D virus as a live vaccine candidate.

Veterinary microbiology·2026
Same journal

Co-infection with CAV facilitates ALV-K replication and induces severe immunosuppression in chickens.

Veterinary microbiology·2026
See all related articles

Area of Science:

  • Immunology
  • Vaccine Development
  • Biotechnology

Background:

  • Purified antigens often lack sufficient immunogenicity for vaccine development.
  • Presenting antigens as multimers on a particle enhances immune recognition.
  • Adjuvants are frequently required to boost immune responses.

Purpose of the Study:

  • To develop a novel vaccine delivery system, the immunostimulating complex (iscom).
  • To assemble antigens into multimeric particles with built-in adjuvants.
  • To evaluate the immunogenicity and efficacy of iscoms against viral pathogens and tumors.

Main Methods:

  • Constructing iscoms by assembling antigens on a matrix with hydrophobic interactions.
  • Testing iscoms in mouse models with influenza virus envelope proteins and feline leukemia virus.

Related Experiment Videos

  • Evaluating iscoms containing Epstein-Barr virus gp360 in a monkey model.
  • Assessing iscoms as carriers for oligopeptides.

    • Main Results:

    • Iscoms demonstrated high immunogenicity, inducing both antibody-mediated and cell-mediated immunity.
    • Intranasal administration of influenza virus iscoms in mice induced protective immunity.
    • Iscoms conferred protective immunity against feline leukemia virus and Epstein-Barr virus-induced tumors.
    • Iscoms carrying oligopeptides were also highly immunogenic.

    Conclusions:

    • Immunostimulating complexes are a potent platform for creating immunogenic vaccines.
    • Iscoms effectively induce protective immunity against diverse viral agents and oncogenic viruses.
    • The iscom technology offers a versatile approach for antigen presentation and adjuvant incorporation.